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On the oligopoly of academic publishers
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A study published in June this year provided convinc-
ing evidence that five for-profit academic publishers 
control more than half of the science research pub-
lished throughout the world [1]. The study considered 
45 million scientific papers covering natural and medi-
cal sciences (NMS) and social sciences and humanities 
(SSH) produced between 1973 and 2013 and indexed 
in the Web of Science.
In both NMS and SSH, Reed-Elsevier, Wiley-Black-
well, Springer and Taylor and Francis are among the 
first five major publishers. In the NMS the American 
Chemical Society is also among the top five, while in 
SSH Sage Publications is included. Thus there is one 
scientific society among the top five in NMS, but all the 
first five in the field of SSH are commercial. In SSH the 
concentration is particularly marked, with around 70% 
of papers published by the top five.
In 1973 the five largest publishers controlled only 
20% of publications; from the 1990s, in particular, the 
larger publishers gradually acquired smaller publishing 
houses and standalone journals. Over the last two de-
cades the diffusion of digital publishing has been a de-
cisive factor in this phenomenon. As Stefanie Haustein, 
one of the authors of the above-mentioned study [1], 
noted, “if they can manage one hundred journals, they 
can manage a thousand (…). The only additional thing 
they need is more server space” [2]. The advent of the 
digital age has also seen the major publishers launching 
the sale of expensive packaged subscriptions to univer-
sities and research institutions: in order to acquire the 
few journals that are really essential for their particular 
disciplines, these institutions are obliged to purchase a 
myriad of esoteric journals as well.
The agreements are still growing: recently the merger 
of Springer Science+Business Media and the major-
ity of Macmillan Science and Education has been an-
nounced [3].
Sadly, all is not well even outside the realm of oli-
gopoly.
The arrival of the digital era has also encouraged the 
rise of open access and its two most obvious manifesta-
tions. The first comprises a few well-known publishing 
groups of recognised scientific quality, such as BMC 
and PLoS; the second comprises the profusion of pred-
atory improvised publishers [4] whose chief aim is to 
extort money from authors. The latter form, which has 
thrown up a superabundance of open access publica-
tions not subjected to peer review, caught the attention 
of, among others, the biologist and scientific journalist 
John Bohannon, who described his experience in “Sci-
ence”. Using the unlikely name Ocarrafoo Cobange 
and claiming to work for the (non-existent) Wassee In-
stitute of Medicine of Asmara, Bohannon submitted to 
304 open access journals an article containing invented 
data, methodological flaws and linguistic errors (artfully 
created by translating the text, through Google, from 
English to French and back again). No fewer than 157 
journals accepted the article [5].
The phenomenon does not seem to diminish: on 18 
August 2015, Springer confirmed that 64 articles are 
being retracted from 10 Springer subscription journals, 
after editorial checks spotted fake email addresses, and 
subsequent internal investigations uncovered fabricat-
ed peer review reports [6].
If we broaden the scope of enquiry further and con-
sider scientific journals not owned by the Big Five and 
not open access, other problems are encountered and 
the debate surrounding the advantages and disadvan-
tages of peer review inevitably becomes further con-
fused. In accepting the Nobel Prize for medicine on 
10th December 2013, and again in an interview with 
The Guardian on the same occasion, Randy Schekman 
fiercely accused the “top journals” of distorting science, 
“just as big bonuses distort banking” and announced 
that his laboratory would cease sending articles to such 
reputedly top-level journals as Nature, Science and Cell 
[7]. He claimed that “The incentives my colleagues face 
are not huge bonuses, but the professional rewards that 
accompany publication in prestigious journals – chiefly 
Nature, Cell and Science. These luxury journals are sup-
posed to be the epitome of quality, publishing only the 
best research. Because funding and appointment panels 
often use place of publication as a proxy for quality of 
science, appearing in these titles often leads to grants 
and professorships. But the “big journals” reputations 
are only partly warranted. While they publish many out-
standing papers, they do not publish only outstanding 
papers. Neither are they the only publishers of outstand-
ing research. These journals aggressively curate their 
brands, in ways more conducive to selling subscriptions 
than to stimulating the most important research. Like 
fashion designers who create limited-edition handbags 
or suits, they know scarcity stokes demand, so they ar-
tificially restrict the number of papers they accept. The 
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exclusive brands are then marketed with a gimmick 
called “impact factor” – a score for each journal, mea-
suring the number of times its papers are cited by sub-
sequent research. Better papers, the theory goes, are 
cited more often, so better journals boast higher scores. 
Yet it is a deeply flawed measure, pursuing which has 
become an end in itself – and is as damaging to science 
as the bonus culture is to banking.
The impossibility of finding satisfactory solutions to 
these problems merely prolongs their influence, while 
researchers continue to depend on the major publishers 
in their search for funds and in pursuing their careers.
Our Institution (Istituto Superiore di Sanità, ISS) is 
the leading technical and scientific body of the Italian 
National Health Service. Its activities include research, 
clinical trials, control and training in public health; it 
also serves as a major national clearing-house for tech-
nical and scientific information on public health issues. 
Since several years ISS has been reflecting on those 
“monopolistic” phenomena, taking action to contrast 
any kind of editorial constraint, discussing internally on 
trends and changes occurring at the national and main-
ly at the sovra-national or global level. This, to both i) 
avoid limitation in the free and non-biased circulation 
of scientific ideas (i.e. in biomedicine, delaying innova-
tive treatment or cure represents a moral and technical 
priority) and ii) possibly nourish a progressive increase 
in the price of journal subscriptions. Promoting open-
access as the most appropriate way for scientific dis-
semination has been therefore an institutional priority 
and the ISS hosted a few meetings [8, 9] and promoted 
position papers [10] on the subject.
Yet, the policy of reducing the increasing power exert-
ed by a very reduced number of editorial entities some-
how controlling the global marked witnessed a major 
step. Already years ago the US National Institutes of 
Health, the major source of biomedical research fund-
ing in Northern America, strongly promoted open-
access dissemination for scientific data collected (and 
the resulting papers published) thanks to its financial 
intervention. And the same is occurring in the case of 
the funding strategies presently carried out by the Euro-
pean Union system of research grant allowance.
Finally, for highly delicate issues such as clinical trial 
policies and their recent trends, the joint co-phenom-
enon of the double monopolistic avenues in reducing 
biomedical publishers and concomitantly (for global-
ized economic and financial attitudes) reducing the 
number of “Big-Pharma-type” drug companies may ex-
plosively endanger the future history of the biomedical 
sciences. This is of course a possibility, not a certainty. 
Yet the echoes which followed the printing of provoca-
tive book by Marcia Angell, for decades Editor-in-chief 
of the prestigious New England Journal of Medicine [11] 
are still vividly buzzing around in the scientific com-
munity.
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